Our innovative therapies target cancer cells, protect healthy tissue, and harness the body’s innate immune response. Our mission is to enhance the power of radiation therapy (RT) while minimizing its side effects. By leveraging our drug discovery and proprietary diagnostic technologies, we aim to increase cancer cure rates and improve quality of life when these drugs are used in combination with radiation therapy.

Using our platform technology to discover novel small molecules to modify the effects of ionizing radiation on cancer cells we have developed a strong portfolio of patented selective histone deacetylase (HDAC) inhibitors. Our strategic collaborations and relationships with academic research institutions have enabled the discovery and exclusive licensing of novel diagnostic technologies for prostate cancer patient management.

Currently, we have a Phase II clinical-stage lead product (Ropidoxuridine), three candidate pre-clinical products (HDAC inhibitors) and are aiming to develop pretreatment diagnostic blood tests for prostate cancer patients.